Key result
Cotreatment with insulin and losartan drastically increased insulin-receptor density and significantly reduced ETB-R expression in the cardiomyocytes of diabetic rats.
Why the study?
Does treatment with insulin and/or an ARB alter insulin and endothelin-1 receptor regulation in the hearts of rats with type-1 diabetes?
Does treatment with insulin and/or an ARB alter insulin and endothelin-1 receptor regulation in the hearts of rats with type-1 diabetes?
Cotreatment with insulin and an ARB modulates insulin and endothelin receptor expression in diabetic rat hearts, potentially explaining benefits in halting myocardial remodeling.
Should not change clinical practice in diabetic cardiomyopathy; leaves open receptor modulation by insulin-ARB cotreatment as a remodeling mechanism.
This project assesses the treatment role with insulin and (or) angiotensin II receptor subtype-1 (AT1-R) blocker (ARB) on insulin receptor and endothelin-1 receptor subtype (ETA-R and ETB-R) regulation in rat hearts suffering from insulin-dependent diabetes mellitus (IDDM). Animals were divided into 6 groups: groups 1, 3, and 5 were controls consisting of normal, diabetic (streptozotocin-treated, once at 0 time), and diabetic supplemented daily with insulin, respectively, whereas groups 2, 4, and 6 were the controls treated daily with losartan. One month after enrollment, rats were sacrificed and samples of cardiac tissue were snapped frozen for immunostaining and Western blotting. Insulin receptor density was observed to be upregulated in the cardiomyocytes of diabetic animals, but downregulated with insulin supplementation alone. Cotreatment with insulin and an ARB resulted in drastic increase in insulin-receptor density in the diabetic rats. In addition, expression of ETA-R in cardiomyocytes was upregulated and was consistently maintained within the various treatment modalities. However, ETB-R expression was significantly reduced in the diabetic group treated with both insulin and an ARB. The changes in the expression of the insulin, the ETA-Rs, and the ETB-Rs at the various sites of the myocardium and the effect of both insulin treatment and blockade of the AT1-R explain the new benefits related to the halting of myocardial remodeling in IDDM rats.
No takes yet. Share an insight, caveat, or question.
Nuwayri‐Salti et al. (2007) studied Insulin-dependent diabetes mellitus (IDDM). Insulin and/or losartan vs. Normal controls and untreated diabetic controls was evaluated on Insulin receptor and endothelin-1 receptor subtype (ETA-R and ETB-R) regulation. Cotreatment with insulin and losartan drastically increased insulin-receptor density and significantly reduced ETB-R expression in the cardiomyocytes of diabetic rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: